Orin Biosciences (688319.SH): The data and conclusions used in the online circulated "Audit Report on Phase III Clinical Data of Recombinant Golden Yeast Vaccine (rFSAV)" are inconsistent with the actual situation of the company's clinical trials.

Intelligent Finance and Economics News APP reports that Orlin Biotech (688319.SH) has issued an announcement. Recently, the company has noticed that there are some false statements on certain online platforms regarding the Phase III clinical trial data of the company's recombinant Staphylococcus aureus vaccine (hereinafter referred to as "rFSAV"). After verification, it was found that the data used in the online circulated "Audit Report on Phase III Clinical Data of Recombinant Staphylococcus aureus Vaccine (rFSAV)" such as the number of confirmed cases, total number of subjects and their conclusions do not match the actual situation of the company's clinical trials.